Head-To-Head Survey: Ovid Therapeutics (NASDAQ:OVID) & Ono Pharmaceutical (OTCMKTS:OPHLF)

Ovid Therapeutics (NASDAQ:OVID) and Ono Pharmaceutical (OTCMKTS:OPHLF) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Valuation and Earnings

This table compares Ovid Therapeutics and Ono Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$1.58 million	345.44	-$17.41 million	($0.31)	-9.03
Ono Pharmaceutical	$3.43 billion	2.04	$436.04 million	$1.01	14.75

Ono Pharmaceutical has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Ono Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ovid Therapeutics and Ono Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	N/A	-23.64%	-20.52%
Ono Pharmaceutical	15.04%	9.41%	7.39%

Volatility and Risk

Ovid Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Ono Pharmaceutical has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Ovid Therapeutics and Ono Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1	0	11	1	2.92
Ono Pharmaceutical	0	1	0	0	2.00

Ovid Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 114.29%. Given Ovid Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Ovid Therapeutics is more favorable than Ono Pharmaceutical.

Institutional & Insider Ownership

72.2% of Ovid Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ono Pharmaceutical beats Ovid Therapeutics on 8 of the 15 factors compared between the two stocks.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for epilepsies and other neurological disorders. Its work targets conditions with significant unmet treatment needs, including rare and difficult-to-treat seizure disorders. The company’s lead development program, OV329, is an investigational GABA aminotransferase inhibitor being studied as a potential treatment for seizures, including infantile spasms and focal-onset seizures. Ovid’s pipeline and research programs may change as clinical development progresses.

About Ono Pharmaceutical

Ono Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Founded in 1717 as a medicine wholesaler, the company is headquartered in Osaka. Ono’s research and product portfolio spans areas including oncology, immunology, neurology and diabetes. A notable product is Opdivo (nivolumab), an immuno-oncology medicine developed through a collaboration involving Ono and Medarex, which was later acquired by Bristol Myers Squibb.